BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 36570815)

  • 1. [Environment and cardiovascular health: causes, consequences and opportunities in prevention and treatment].
    Bañeras J; Iglesies-Grau J; Téllez-Plaza M; Arrarte V; Báez-Ferrer N; Benito B; Campuzano Ruiz R; Cecconi A; Domínguez-Rodríguez A; Rodríguez-Sinovas A; Ujueta F; Vozzi C; Lamas GA; Navas-Acién A
    Rev Esp Cardiol; 2022 Dec; 75(12):1050-1058. PubMed ID: 36570815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Environment and cardiovascular health: causes, consequences and opportunities in prevention and treatment.
    Bañeras J; Iglesies-Grau J; Téllez-Plaza M; Arrarte V; Báez-Ferrer N; Benito B; Campuzano Ruiz R; Cecconi A; Domínguez-Rodríguez A; Rodríguez-Sinovas A; Ujueta F; Vozzi C; Lamas GA; Navas-Acién A
    Rev Esp Cardiol (Engl Ed); 2022 Dec; 75(12):1050-1058. PubMed ID: 35931285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline characteristics including blood and urine metal levels in the Trial to Assess Chelation Therapy 2 (TACT2).
    Navas-Acien A; Santella RM; Joubert BR; Huang Z; Lokhnygina Y; Ujueta F; Gurvich I; LoIacono NJ; Ravalli F; Ward CD; Jarrett JM; Salazar AL; Boineau R; Jones TLZ; Mark DB; Newman JD; Nathan DM; Anstrom KJ; Lamas GA
    Am Heart J; 2024 Jul; 273():72-82. PubMed ID: 38621575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The trial to assess chelation therapy 2 (TACT2): Rationale and design.
    Lamas GA; Anstrom KJ; Navas-Acien A; Boineau R; Kim H; Rosenberg Y; Stylianou M; Jones TLZ; Joubert BR; Santella RM; Escolar E; Aude YW; Fonseca V; Elliott T; Lewis EF; Farkouh ME; Nathan DM; Mon AC; Gosnell L; Newman JD; Mark DB;
    Am Heart J; 2022 Oct; 252():1-11. PubMed ID: 35598636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy.
    Lamas GA; Navas-Acien A; Mark DB; Lee KL
    J Am Coll Cardiol; 2016 May; 67(20):2411-2418. PubMed ID: 27199065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Minderoo-Monaco Commission on Plastics and Human Health.
    Landrigan PJ; Raps H; Cropper M; Bald C; Brunner M; Canonizado EM; Charles D; Chiles TC; Donohue MJ; Enck J; Fenichel P; Fleming LE; Ferrier-Pages C; Fordham R; Gozt A; Griffin C; Hahn ME; Haryanto B; Hixson R; Ianelli H; James BD; Kumar P; Laborde A; Law KL; Martin K; Mu J; Mulders Y; Mustapha A; Niu J; Pahl S; Park Y; Pedrotti ML; Pitt JA; Ruchirawat M; Seewoo BJ; Spring M; Stegeman JJ; Suk W; Symeonides C; Takada H; Thompson RC; Vicini A; Wang Z; Whitman E; Wirth D; Wolff M; Yousuf AK; Dunlop S
    Ann Glob Health; 2023; 89(1):23. PubMed ID: 36969097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible differential benefits of edetate disodium in post-myocardial infarction patients with diabetes treated with different hypoglycemic strategies in the Trial to Assess Chelation Therapy (TACT).
    Escolar E; Ujueta F; Kim H; Mark DB; Boineau R; Nahin RL; Goertz C; Lee KL; Anstrom KJ; Lamas GA
    J Diabetes Complications; 2020 Aug; 34(8):107616. PubMed ID: 32446881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contaminant Metals as Cardiovascular Risk Factors: A Scientific Statement From the American Heart Association.
    Lamas GA; Bhatnagar A; Jones MR; Mann KK; Nasir K; Tellez-Plaza M; Ujueta F; Navas-Acien A;
    J Am Heart Assoc; 2023 Jul; 12(13):e029852. PubMed ID: 37306302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes.
    Ouyang P; Gottlieb SH; Culotta VL; Navas-Acien A
    Curr Cardiol Rep; 2015 Nov; 17(11):96. PubMed ID: 26364188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Environmental cardiology: studying mechanistic links between pollution and heart disease.
    Bhatnagar A
    Circ Res; 2006 Sep; 99(7):692-705. PubMed ID: 17008598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Role of Metal Chelation to Prevent the Cardiovascular Complications of Diabetes.
    Calderon Moreno R; Navas-Acien A; Escolar E; Nathan DM; Newman J; Schmedtje JF; Diaz D; Lamas GA; Fonseca V
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2931-2941. PubMed ID: 30869793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ecology of the cardiovascular system: A focus on air-related environmental factors.
    Argacha JF; Bourdrel T; van de Borne P
    Trends Cardiovasc Med; 2018 Feb; 28(2):112-126. PubMed ID: 28826667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT).
    Escolar E; Lamas GA; Mark DB; Boineau R; Goertz C; Rosenberg Y; Nahin RL; Ouyang P; Rozema T; Magaziner A; Nahas R; Lewis EF; Lindblad L; Lee KL
    Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):15-24. PubMed ID: 24254885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality and Morbidity Effects of Long-Term Exposure to Low-Level PM
    Brunekreef B; Strak M; Chen J; Andersen ZJ; Atkinson R; Bauwelinck M; Bellander T; Boutron MC; Brandt J; Carey I; Cesaroni G; Forastiere F; Fecht D; Gulliver J; Hertel O; Hoffmann B; de Hoogh K; Houthuijs D; Hvidtfeldt U; Janssen N; Jorgensen J; Katsouyanni K; Ketzel M; Klompmaker J; Hjertager Krog N; Liu S; Ljungman P; Mehta A; Nagel G; Oftedal B; Pershagen G; Peters A; Raaschou-Nielsen O; Renzi M; Rodopoulou S; Samoli E; Schwarze P; Sigsgaard T; Stafoggia M; Vienneau D; Weinmayr G; Wolf K; Hoek G
    Res Rep Health Eff Inst; 2021 Sep; 2021(208):1-127. PubMed ID: 36106702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personal-Level Protective Actions Against Particulate Matter Air Pollution Exposure: A Scientific Statement From the American Heart Association.
    Rajagopalan S; Brauer M; Bhatnagar A; Bhatt DL; Brook JR; Huang W; Münzel T; Newby D; Siegel J; Brook RD;
    Circulation; 2020 Dec; 142(23):e411-e431. PubMed ID: 33150789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chelation therapy to prevent diabetes-associated cardiovascular events.
    Diaz D; Fonseca V; Aude YW; Lamas GA
    Curr Opin Endocrinol Diabetes Obes; 2018 Aug; 25(4):258-266. PubMed ID: 29846236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chelation Therapy as a Cardiovascular Therapeutic Strategy: the Rationale and the Data in Review.
    Mathew RO; Schulman-Marcus J; Nichols EL; Newman JD; Bangalore S; Farkouh M; Sidhu MS
    Cardiovasc Drugs Ther; 2017 Dec; 31(5-6):619-625. PubMed ID: 29129003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider?
    Lamas GA; Ergui I
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):927-38. PubMed ID: 27149141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Social Susceptibility to Multiple Air Pollutants in Cardiovascular Disease.
    Clougherty JE; Humphrey JL; Kinnee EJ; Robinson LF; McClure LA; Kubzansky LD; Reid CE
    Res Rep Health Eff Inst; 2021 Jul; 2021(206):1-71. PubMed ID: 36004603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.